Retatrutide produced up to 30.3% mean body weight loss in Phase 3 TRIUMPH-1 — the highest ever recorded for an obesity medication. FDA approval expected in 2027. Be first in line for physician-supervised access.
Your information is stored securely and never sold or shared. No PHI collected.
Every approved GLP-1 medication works by targeting one or two metabolic pathways. Retatrutide targets three simultaneously — producing weight loss that dwarfs anything previously seen in a Phase 3 obesity trial.
GLP-1 receptor agonism slows gastric emptying and signals satiety to the brain, reducing caloric intake. This is the same mechanism behind semaglutide and tirzepatide.
GIP receptor agonism improves insulin secretion and adipose tissue metabolism, enhancing the body's ability to utilize nutrients efficiently. Shared with tirzepatide.
Glucagon receptor agonism increases resting metabolic rate and promotes fat oxidation in the liver. This is retatrutide's key differentiator — no other approved drug does this.
The combination produces weight loss that approaches surgical outcomes in some patients — without surgery. TRIUMPH-4 reported complete knee pain relief in 1 in 8 participants.
In the Phase 3 TRIUMPH-1 trial (n=2,339), participants receiving retatrutide 12mg lost a mean
of 28.3% of body weight at 80 weeks — and up to 30.3% at 104 weeks in the BMI ≥35 extension.
All three doses met all primary and key secondary endpoints.
How retatrutide compares to currently approved medications at maximum doses:
| Medication | Mechanism | Mean Weight Loss |
|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | |
| Tirzepatide (Zepbound) | GLP-1 + GIP | |
| Retatrutide (investigational) | GLP-1 + GIP + Glucagon |
Data from published Phase 2 and Phase 3 clinical trials. Retatrutide is investigational and not FDA approved. Direct comparisons across trials should be interpreted cautiously.
Based on Eli Lilly's public statements and standard FDA review timelines. These are projections, not confirmed dates.
Join the waitlist now. When retatrutide is approved, you'll be among the first to access it through a licensed physician.